Author

P. Taimen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Organism:zebrafish· 2

Frequent Co-Authors

I. Paatero· 3 shared A. Padzik· 2 shared J. Ivaska· 2 shared A. Aakula· 1 shared A. Erickson· 1 shared A. Isomursu· 1 shared A. Jawahar-Deen· 1 shared A. Jokilammi· 1 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

I. Paatero

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

STAT5b is a key effector of NRG-1/ERBB4-mediated cardiomyocyte growth

K. M. Vaparanta, A. Jokilammi, I. Paatero, J. A. M. Merilahti, J. Heliste, K. A. Hemanthakumar, R. Kivelä, K. K. Alitalo, P. Taimen, K. Elenius

This study identifies STAT5b as a critical mediator of NRG-1/ERBB4-induced cardiomyocyte growth and shows its dysregulation in cardiac hypertrophy.

bioRxiv · Oct 5, 2022 · PreprintCell Biology

Pan-cancer scale screening reveals NRF2 associated immunoevasive characteristics in non-small cell lung cancer and squamous malignancies

J. Harkonen, P. Polonen, A. Jawahar-Deen, I. Selvarajan, H.-R. Teppo, E. Dimova, T. Kietzmann, M. Ahtiainen, T. Eklund, T. Kuopio, E.-M. Talvitie, P. Taimen, M. Kallajoki, M. U. Kaikkonen, M. Heinaniemi, A.-L. Levonen

This paper identifies NRF2-associated immunoevasive features in NSCLC and squamous cancers, linking NRF2 activity to immune-cold phenotypes and potential biomarkers for immune checkpoint response.

bioRxiv · May 15, 2022 · PreprintCancer Biology

PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers

A. Aakula, A. Isomursu, C. Rupp, A. Erickson, O. Kauko, P. Shah, A. Padzik, Y. R. Pokharel, A. Kaur, S.-P. Li, L. Trottman, P. Taimen, A. Rannikko, J. Lammerding, I. Paatero, , J. Westermarck

This study identifies PME-1 as a biomarker for aggressive PTEN-deficient prostate cancers by showing its role in suppressing anoikis.

bioRxiv · Mar 17, 2022 · PreprintCancer Biology

SORLA-driven endosomal trafficking regulates the oncogenic fitness of HER2

M. Pietila, P. Sahgal, E. Peuhu, N. Jantti, I. Paatero, O. M. Andersen, A. Padzik, M. Blomqvist, I. Saarinen, P. Bostrom, P. Taimen, J. Ivaska

This study shows SORLA regulates HER2 trafficking, affecting its oncogenic activity and response to therapy.

bioRxiv · Apr 11, 2018Cell Biology